Merck & Co., Inc. is 105.7x more valuable than Arcus Biosciences, Inc. by market capitalization ($294.13 B vs $2.78 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RCUS | MRK |
|---|---|---|
| Market cap | $2.78 B | $294.13 B |
| US-listed rank | #1869 | #44 |
| Revenue (latest FY) | $247.00M | $65.01B |
| Net income (latest FY) | -$353.00M | $18.25B |
| Net margin | -142.9% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 567 | 996 |
Merck & Co., Inc. is 105.7x more valuable than Arcus Biosciences, Inc. by market capitalization ($294.13 B vs $2.78 B).
In their latest fiscal years, Arcus Biosciences, Inc. reported $247.00M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Arcus Biosciences, Inc. and Merck & Co., Inc., or browse the full rankings.